$10.48
arrow_drop_down5.84%Key Stats | |
---|---|
Open | $11.23 |
Prev. Close | $11.13 |
EPS | -3.27 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 10.62 | 11.43 |
52 Week Range | 4.92 | 18.12 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -3.27 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Anaveon appoints Dieter Weinand as Chair of its Board of Directors
Advanced Melanoma Clinical Trial Pipeline Analysis - GlobeNewswire
Replimune (REPL) Gains on Positive Data From Melanoma Study
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma